During the past decade, The Minnesota Cystic Fibrosis Center conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Minnesota Cystic Fibrosis Center" #1 sponsor was "Nicole Hamblett" with 4 trials, followed by "Amalia Magaret" with 1 trials sponsored, "Chris Goss" with 1 trials sponsored, "Merck Sharp & Dohme LLC" with 1 trials sponsored and "Seattle Children's Hospital" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Minnesota Cystic Fibrosis Center" #1 collaborator was "Cystic Fibrosis Foundation" with 9 trials as a collaborator, "University of Texas" with 2 trials as a collaborator, "University of Washington" with 2 trials as a collaborator, "CF Therapeutics Development Network Coordinating Center" with 1 trials as a collaborator and "Dartmouth-Hitchcock Medical Center" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "The Minnesota Cystic Fibrosis Center" are "Cystic Fibrosis" (10 trials), "Cystic Fibrosis in Children" (1 trials) and "Pregnancy Related" (1 trials). Many other conditions were trialed in "The Minnesota Cystic Fibrosis Center" in a lesser frequency.

Most popular intervention types in "The Minnesota Cystic Fibrosis Center" are "Drug" (3 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Continuation of dornase alfa (dnase)" (1 trials), "Continuation of hypertonic saline (HS)" (1 trials), "Discontinuation of dornase alfa (dnase)" (1 trials), "Discontinuation of hypertonic saline (HS)" (1 trials) and "Ivacaftor or elexacaftor/tezacaftor/ivacaftor" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Minnesota Cystic Fibrosis Center" are 9 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "The Minnesota Cystic Fibrosis Center". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in The Minnesota Cystic Fibrosis Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Minnesota Cystic Fibrosis Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".